StocksMedium•16 October 2026•
1 min read
Omeros Stock Falls as EMA Upholds Negative Opinion on Narsoplimab
Key Facts
1The EMA’s CHMP upheld its negative opinion on narsoplimab for the treatment of TA-TMA.
2Omeros announced the termination of its compassionate-use program for the drug following the decision.
The EMA’s CHMP upheld its negative opinion on narsoplimab for the treatment of TA-TMA. Benzinga reported that Omeros Corporation announced the termination of its compassionate-use program for the drug following the regulatory decision.
OMER closed at $18.79 on October 15, 2026, after reaching a session high of $19.08 and a low of $18.3. The reaffirmed rejection by the European regulator effectively blocks the drug's path to approval in the EU, impacting the firm's clinical outlook.